NO2579874T3 - - Google Patents

Info

Publication number
NO2579874T3
NO2579874T3 NO11728037A NO11728037A NO2579874T3 NO 2579874 T3 NO2579874 T3 NO 2579874T3 NO 11728037 A NO11728037 A NO 11728037A NO 11728037 A NO11728037 A NO 11728037A NO 2579874 T3 NO2579874 T3 NO 2579874T3
Authority
NO
Norway
Application number
NO11728037A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2579874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2579874T3 publication Critical patent/NO2579874T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO11728037A 2010-06-08 2011-06-06 NO2579874T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (1)

Publication Number Publication Date
NO2579874T3 true NO2579874T3 (cg-RX-API-DMAC7.html) 2018-06-09

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11728037A NO2579874T3 (cg-RX-API-DMAC7.html) 2010-06-08 2011-06-06

Country Status (32)

Country Link
US (1) US8921387B2 (cg-RX-API-DMAC7.html)
EP (3) EP2579874B1 (cg-RX-API-DMAC7.html)
JP (2) JP5986072B2 (cg-RX-API-DMAC7.html)
KR (1) KR101865689B1 (cg-RX-API-DMAC7.html)
CN (1) CN103079544B (cg-RX-API-DMAC7.html)
AU (1) AU2011263478B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012031290A2 (cg-RX-API-DMAC7.html)
CA (1) CA2801676C (cg-RX-API-DMAC7.html)
CL (1) CL2012003462A1 (cg-RX-API-DMAC7.html)
CO (1) CO6670529A2 (cg-RX-API-DMAC7.html)
CY (1) CY1120761T1 (cg-RX-API-DMAC7.html)
DK (2) DK2579874T3 (cg-RX-API-DMAC7.html)
ES (2) ES2656938T3 (cg-RX-API-DMAC7.html)
FI (1) FI3360538T3 (cg-RX-API-DMAC7.html)
GB (2) GB2481018B (cg-RX-API-DMAC7.html)
HR (1) HRP20180118T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038275T2 (cg-RX-API-DMAC7.html)
IL (2) IL223488A (cg-RX-API-DMAC7.html)
LT (1) LT2579874T (cg-RX-API-DMAC7.html)
MX (1) MX339209B (cg-RX-API-DMAC7.html)
MY (1) MY171625A (cg-RX-API-DMAC7.html)
NO (1) NO2579874T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ604026A (cg-RX-API-DMAC7.html)
PL (1) PL2579874T3 (cg-RX-API-DMAC7.html)
PT (1) PT2579874T (cg-RX-API-DMAC7.html)
RS (1) RS56820B1 (cg-RX-API-DMAC7.html)
RU (1) RU2607498C2 (cg-RX-API-DMAC7.html)
SG (1) SG186200A1 (cg-RX-API-DMAC7.html)
SI (1) SI2579874T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800038T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011154724A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201209233B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
NZ631539A (en) 2012-04-17 2016-10-28 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
MX387722B (es) 2012-07-26 2025-03-18 Camurus Ab Formulaciones de opioides.
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
KR102505642B1 (ko) * 2013-03-15 2023-03-06 헤론 테라퓨틱스 인코포레이티드 폴리오르토에스테르 및 비프로톤성 용매의 조성물
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
EP3509601A1 (en) 2014-04-21 2019-07-17 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
EP3785700A1 (en) * 2014-04-21 2021-03-03 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
KR20220138419A (ko) 2014-04-21 2022-10-12 헤론 테라퓨틱스 인코포레이티드 장기간 작용하는 중합체 전달 시스템
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
JP6568102B2 (ja) 2014-04-28 2019-08-28 オーフォームド,インコーポレイティド ブプレノルフィン二量体及び消化管疾患の治療におけるその使用
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
ES2808150T3 (es) * 2014-11-07 2021-02-25 Indivior Uk Ltd Regímenes de dosificación de buprenorfina
KR102696721B1 (ko) * 2015-08-03 2024-08-19 톨마 인터내셔날 리미티드 약물의 장기간 지속적인 투여를 위한 액체 폴리머 전달 시스템
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
FI3512518T3 (fi) * 2016-09-13 2023-01-31 Hitaasti vapautuvia buprenorfiiniformulaatioita
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
CN112236142A (zh) 2018-01-22 2021-01-15 逸达生物科技股份有限公司 用于缓释递送丁丙诺啡的药物组合物
NZ766474A (en) * 2018-05-11 2023-03-31 Alar Pharmaceuticals Inc Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
AU2019357036B2 (en) 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2582666C (en) 1994-04-08 2010-05-25 Qlt Usa, Inc. Controlled release implant
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
NZ536965A (en) * 2002-05-31 2007-02-23 Titan Pharmaceuticals Inc Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
PL377333A1 (pl) * 2002-11-06 2006-01-23 Alza Corporation Preparaty depot o kontrolowanym uwalnianiu
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
MX2007003789A (es) * 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
RS53890B1 (sr) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
ES2550014T3 (es) 2007-02-15 2015-11-03 Tolmar Therapeutics, Inc. Poli-(lactida/glicolida) de descarga lenta y métodos para producir polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
JP2016155865A (ja) 2016-09-01
PT2579874T (pt) 2018-01-29
FI3360538T3 (fi) 2023-03-22
MX2012014335A (es) 2013-03-05
ES2939612T3 (es) 2023-04-25
WO2011154724A3 (en) 2012-07-12
CO6670529A2 (es) 2013-05-15
ZA201209233B (en) 2014-04-30
SMT201800038T1 (it) 2018-03-08
CL2012003462A1 (es) 2013-04-01
GB2481018A (en) 2011-12-14
GB201009549D0 (en) 2010-07-21
GB201413064D0 (en) 2014-09-03
EP3360538B1 (en) 2023-02-15
PL2579874T3 (pl) 2018-05-30
GB2481018B (en) 2015-03-18
CA2801676A1 (en) 2011-12-15
IL223488A (en) 2017-10-31
EP4218720A1 (en) 2023-08-02
MX339209B (es) 2016-04-15
RU2012157244A (ru) 2014-07-20
HUE038275T2 (hu) 2018-10-29
EP2579874A2 (en) 2013-04-17
BR112012031290A2 (pt) 2016-11-01
SG186200A1 (en) 2013-01-30
MY171625A (en) 2019-10-21
EP3360538A1 (en) 2018-08-15
RU2607498C2 (ru) 2017-01-10
ES2656938T3 (es) 2018-03-01
KR101865689B1 (ko) 2018-06-08
DK2579874T3 (da) 2018-01-29
CY1120761T1 (el) 2019-12-11
EP2579874B1 (en) 2018-01-10
AU2011263478B2 (en) 2015-01-22
CA2801676C (en) 2018-08-07
AU2011263478A1 (en) 2013-01-10
WO2011154724A2 (en) 2011-12-15
JP5986072B2 (ja) 2016-09-06
SI2579874T1 (en) 2018-03-30
KR20130135026A (ko) 2013-12-10
DK3360538T3 (da) 2023-03-06
US20130210853A1 (en) 2013-08-15
CN103079544A (zh) 2013-05-01
JP6251774B2 (ja) 2017-12-20
WO2011154724A9 (en) 2012-08-16
CN103079544B (zh) 2017-06-09
HRP20180118T1 (hr) 2018-03-09
RS56820B1 (sr) 2018-04-30
NZ604026A (en) 2015-01-30
JP2013533230A (ja) 2013-08-22
LT2579874T (lt) 2018-02-12
GB2513267B (en) 2015-03-18
GB2513267A (en) 2014-10-22
US8921387B2 (en) 2014-12-30
IL254417A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112013008959A2 (cg-RX-API-DMAC7.html)
BR112012030039A2 (cg-RX-API-DMAC7.html)
BR112012028408A2 (cg-RX-API-DMAC7.html)
BR112012029986A2 (cg-RX-API-DMAC7.html)
BR112012027808A2 (cg-RX-API-DMAC7.html)
BR112012024897A2 (cg-RX-API-DMAC7.html)
BR112012026492A2 (cg-RX-API-DMAC7.html)
BR112012031500A2 (cg-RX-API-DMAC7.html)
BR112012026946A2 (cg-RX-API-DMAC7.html)
BR112012025482A2 (cg-RX-API-DMAC7.html)
BR112013006400A2 (cg-RX-API-DMAC7.html)
BR112012031826A2 (cg-RX-API-DMAC7.html)
BR112012023249A2 (cg-RX-API-DMAC7.html)
BR112012025577A2 (cg-RX-API-DMAC7.html)
BR112012028186A2 (cg-RX-API-DMAC7.html)
NO2579874T3 (cg-RX-API-DMAC7.html)
BR112012027015A2 (cg-RX-API-DMAC7.html)
BR112012025308A2 (cg-RX-API-DMAC7.html)
BR112013010949A2 (cg-RX-API-DMAC7.html)
BR112012027945A2 (cg-RX-API-DMAC7.html)
BR112012024872A2 (cg-RX-API-DMAC7.html)
BR112012023265A2 (cg-RX-API-DMAC7.html)
BR112013003284A2 (cg-RX-API-DMAC7.html)
BR112012026403A2 (cg-RX-API-DMAC7.html)
BR112013002646A2 (cg-RX-API-DMAC7.html)